ARF market seen reaching $9.71 billion by 2030

The acute renal failure market is projected to grow from $6.6 billion in 2025 to $9.71 billion by 2030, driven by higher rates of diabetes, hypertension and chronic kidney disease. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Acute renal failure, also known as acute kidney injury, can quickly worsen kidney function and raise the risk of long-term damage. - The market’s growth points to rising demand for hospital care, dialysis, diagnostics and kidney-protective treatments. - Chronic kidney disease is a major underlying pressure on treatment demand because acute renal failure can trigger or accelerate further kidney decline.

What happened: - The Business Research Company projected the global acute renal failure market will rise from $6.6 billion in 2025 to $7.14 billion in 2026. - The report forecast the market will reach $9.71 billion by 2030. - The company said the market is growing from rising health concerns, treatment advances and an aging population. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - The 2026 market outlook implies 8.3% growth from 2025 to 2026. - The 2030 forecast reflects an 8.0% compound annual growth rate from 2026 to 2030. - Near-term growth is tied to higher rates of hypertension and diabetes. - Hospital-based renal care and broader hospital infrastructure are supporting market expansion. - Limited recognition of early ARF symptoms is also shaping treatment demand. - Conventional dialysis remains widely used in ARF care. - The report expects new nephroprotective drugs, AI-assisted diagnostics and home healthcare services to add momentum. - The report also points to an expanding elderly population and higher investment in renal disease research. - Key trends include broader adoption of advanced dialysis and renal support therapies. - Early detection of acute kidney injury is becoming a stronger focus. - Use of nephroprotective medications is increasing. - Imaging and biopsy-based diagnostic technologies are expanding. - Home healthcare management is becoming a more common preference among ARF patients. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market forecast suggests ARF care is shifting from a narrow acute-treatment focus toward earlier detection, more advanced diagnostics and more care outside the hospital. - The chronic kidney disease backdrop strengthens the case for ARF spending because kidney injuries can compound long-term disease burden. - Kidney Research UK said in June 2023 that about 7.2 million people in the UK, or more than 10% of the population, were living with CKD. - That UK total included 3.25 million people in advanced stages and 3.9 million in early stages. - Kidney Research UK projected the UK CKD population will rise to 7.61 million by 2033.

What's next: - Market growth will likely track adoption of nephroprotective drugs, AI tools and home-based care models. - The strongest regional growth is expected to come from Asia-Pacific. - The report positions early detection and advanced renal support as the main areas to watch through 2030.

The bottom line: - ARF care is moving into a larger, faster-growing market as kidney disease risk rises and treatment options broaden. - More information is available in the company's announcement and the free sample report.